Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 84

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 84
---
.

We may face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use of our product candidates harms patients or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims.

In carrying out our activities,
we may potentially face contractual and statutory claims, or other types of claims from customers, suppliers and/or investors. In addition,
we are exposed to potential product liability risks that are inherent in the research, development, production and supply of products.
Subjects enrolled in our clinical trials, consumers, healthcare providers or other persons administering or selling products based on
our and our collaborators’ technology may be able to bring claims against us based on the use of such products. If we cannot successfully
defend ourselves against claims that any product candidates commercialized caused injuries, we could incur substantial costs and liabilities.
Irrespective of their merits or actual outcome, liability claims may result in:

| • | decreased demand for any product candidates that we may develop; |

| • | withdrawal of clinical trial participants; |

| • | termination of clinical trials; |

| • | significant negative media attention and injury to our reputation; |

| • | significant costs to defend the related litigation; |

| 42 |

| • | substantial monetary awards to trial subjects or patients; |

| • | loss of revenue; |

| • | diversion of management and scientific resources from our business operations; and |

| • | the inability to commercialize any products that we may develop. |

While we have obtained product
liability coverage, our insurance coverage may not be sufficient to cover our entire product liability related expenses or losses and
may not cover us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the
future, we may not be able to maintain insurance coverage at a reasonable cost, in sufficient amounts or upon adequate terms to protect
us against losses due to product liability. If we determine that it is prudent to increase our product liability, we may be unable to
obtain this increased product liability insurance on commercially reasonable terms or at all. Large judgments have been awarded in class
action or individual lawsuits based on drugs that had unanticipated side effects, including side effects that may be less severe than
those of our products. A successful product liability claim or series of claims brought against us could cause the price of the Ordinary